1. Home
  2. EXPD vs UTHR Comparison

EXPD vs UTHR Comparison

Compare EXPD & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expeditors International of Washington Inc.

EXPD

Expeditors International of Washington Inc.

HOLD

Current Price

$151.33

Market Cap

16.3B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXPD
UTHR
Founded
1979
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.3B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
EXPD
UTHR
Price
$151.33
$488.92
Analyst Decision
Hold
Buy
Analyst Count
10
12
Target Price
$129.22
$495.08
AVG Volume (30 Days)
1.5M
424.3K
Earning Date
11-04-2025
10-29-2025
Dividend Yield
1.02%
N/A
EPS Growth
20.10
16.08
EPS
6.15
26.38
Revenue
$11,167,760,000.00
$3,128,400,000.00
Revenue This Year
$3.06
$13.64
Revenue Next Year
N/A
$5.78
P/E Ratio
$24.64
$18.55
Revenue Growth
12.54
13.50
52 Week Low
$100.47
$266.98
52 Week High
$151.67
$492.62

Technical Indicators

Market Signals
Indicator
EXPD
UTHR
Relative Strength Index (RSI) 75.95 68.10
Support Level $144.93 $470.13
Resistance Level $147.87 $492.62
Average True Range (ATR) 2.89 10.72
MACD 0.18 -0.53
Stochastic Oscillator 98.14 89.55

Price Performance

Historical Comparison
EXPD
UTHR

About EXPD Expeditors International of Washington Inc.

Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: